Placebo response remains one of the most persistent challenges in dermatology clinical trials, often blurring the line between genuine treatment efficacy and perceived improvement. The issue becomes even more complex in rare dermatologic indications, where small patient populations and subjective or visual assessments heighten variability.

This webinar explores why placebo rates are disproportionately high in dermatology studies and offers evidence-based strategies to minimize their impact—helping sponsors strengthen data credibility and optimize study outcomes.

Discover key insights from industry experts as they discuss how these changes are reshaping trial accountability and what proactive steps sponsors can take to ensure compliant oversight while maintaining operational efficiency. Our presenters include Mesfin James (Vice President, Head of Regulatory Affairs), Mihaly Imre (Senior Medical Director), and Sonja VanWye (Project Director, Dermatology).

In this webinar, you’ll learn how to:

• Identify and mitigate placebo risk factors early in trial planning
• Strengthen study design, site training, and patient engagement
• Navigate new regulatory expectations for transparency and documentation
• Protect study integrity and data reliability in an increasingly visible research environment

Fill out the form to watch the webinar and gain practical strategies for managing placebo risk and ensuring credible, compliant dermatology trial results.